Heather A. Berger - Jul 16, 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc. (ETTX)

Role
Director
Signature
Elizabeth M. Keiley as Attorney-in-Fact for Heather Behanna
Stock symbol
ETTX
Transactions as of
Jul 16, 2021
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 03:02 PM
Previous filing
Jun 16, 2021
Next filing
Jan 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETTX Stock Option (Right to Buy) Disposed to Issuer -15K -100% 0 Jul 16, 2021 Common Stock 15K $5.66 Direct F1, F2
transaction ETTX Stock Option (Right to Buy) Award +11.5K 11.5K Jul 16, 2021 Common Stock 11.5K $2.44 Direct F2, F3
transaction ETTX Stock Option (Right to Buy) Disposed to Issuer -7.5K -100% 0 Jul 16, 2021 Common Stock 7.5K $6.12 Direct F4, F5
transaction ETTX Stock Option (Right to Buy) Award +5.77K 5.77K Jul 16, 2021 Common Stock 5.77K $2.44 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option provided for vesting as follows: The shares subject to this option will vest in full on January 1, 2020, subject to the Reporting Person's continued service through such vesting date.
F2 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share.
F3 The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
F4 The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date.
F5 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share.
F6 The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.